MD, Higher Medical Institute Varna
Maimonides Medical Center
The Mount Sinai Hospital
Fellowship, Child and Adolescent Psychiatry
The Mount Sinai Hospital
Child & Adolescent Psychiatry
Psychiatry, American Board of Psychiatry and Neurology
Ivanov I, Charney A. Current trends in the use of antipsychotics in pediatric patients [review]. The Mount Sinai Journal of Medicine 2008 May-June; 75(3): 276-286.
Ivanov I, Schulz K, London E. Inhibitory Control Deficits in Childhood and Risk for Substance Use Disorders. The American Journal of Drug and Alcohol Abuse 2008; 34(3): 239-258.
Newcorn J, Ivanov I. Psychopharmacological Treatment of Attention-Deficit/Hyperactivity Disorder and Disruptive Behavior Disorders-review. In: Arnold L, editor. Special Issue on Pediatric Psychopharmacology (July 2007). Psychiatric Annals; pp37(7).
Ivanov I. Common Problems in Psychotherapy Training for Psychiatry Residents. Journal of Psychiatric Practice 2007 May; 13(3): 184-189.
Ivanov I, Klein M, Green WH. The Challenges of Psychopharmacological Management of Children with Severe Developmental Disabilities: a Clinical Case. Journal of Child and Adolescent Psychopharmacology 2006 Dec; 16(6): 793-799.
Ivanov I, Schulz KP, Palmero R, Newcorn JH. Neurobiology and Evidence-based Treatments for Substance Abuse Disorders- Review. CNS Spectrums 2006 Nov; 11(11): 864-877.
Newcorn J, Ivanov I. Risk-Benefit Considerations in ADHD Pharmacotherapy, First Report. Princeton CME 2006 Oct;.
Ivanov I. Case Study Childhood Onset Conduct Disorder for Psychiatry Pearls (2004). Philadelphia, PA, Hanley & Belfus, Inc.;.
Ivanov I. Case Study ADHD/Bipolar Disorder Co-morbidity in Children for Psychiatry Pearls (2004). Philadelphia, PA, Hanley & Belfus, Inc.;.
Newcorn JH, Miller SR, Ivanov I, Schulz KP, Marks D, Halperin JM. Adolescent Outcome of ADHD: Impact of Childhood Conduct and Anxiety Disorders. CNS Spectrums 2004 Sep; 9(9): 668-678.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Ivanov during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.